Navigation Links
Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
Date:8/5/2008

-Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular

Edema-

SUNNYVALE, Calif., Aug. 5 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held ophthalmic pharmaceutical company, announced today that enrollment has been completed in its Phase I clinical trial to assess the safety and efficacy of its lead product, IBI-20089, in patients with cystoid macular edema. This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery.

IBI-20089 is a novel drug product based on IBI's proprietary Verisome(TM) drug delivery platform technology, which is optimally suited for application in the ophthalmic market. IBI-20089 is designed to last up to one year with a single intravitreal injection. It uniquely provides physicians the flexibility to tailor the duration of effect for a particular patient. IBI- 20089 is administered as a standard intravitreal injection without the need for additional devices or surgical procedures.

"We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome(TM) drug delivery technology," said Vernon G. Wong, MD, Founder of Icon Bioscience, Inc. "We believe IBI is creating the future standard of ophthalmic care as evidenced by the development of IBI-20089, the first of many products already in development based on the Verisome(TM) technology."

About Icon Bioscience, Inc.

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary Verisome(TM) drug delivery platform. The Verisome(TM) drug delivery technology encompasses over twenty related but distinct novel and proprietary drug delivery systems optimally suited for appl
'/>"/>

SOURCE Icon Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or ... quality medical marijuana products, is pleased to announce that ... signed a definitive lease agreement for a second facility ... facility has 28,966 square feet of floor space with ... mezzanine space for a total of approximately 43,500 square ...
(Date:9/22/2014)... PLYMOUTH MEETING, Pa. , Sept. 22, 2014 ... ) announced today it has initiated a phase ... The trial will evaluate the safety, tolerability, and ... type 6 (HPV-6), which causes most aerodigestive cancers. ... tongue, nose, throat, vocal cords, and parts of ...
(Date:9/22/2014)... YORK , Sept. 22, 2014 ... exclusive, global license agreement with Plasma Technologies LLC ... proprietary plasma fractionation process. Concurrently, the Company announced ... to strategically refocus and rebrand the company as ... a national listing for its common shares. ...
Breaking Medicine Technology:T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 2T-Bird Pharma Inc. to Increase Growing Capacity with Expansion into a 43,500 square feet Second Facility 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6
... Feb. 18, 2011 Replacing both knees in one ... was associated with significantly fewer prosthetic joint infections as ... after surgery, compared with total knee replacements performed in ... a moderately higher risk of adverse cardiovascular outcomes within ...
... 18, 2011 Novavax, Inc. (Nasdaq: NVAX) ... final safety and immunogenicity results from its 2009 H1N1 ... Mexico at the invitation-only 7th World Health Organization Meeting ... Trials. The meeting was held at the WHO headquarters ...
Cached Medicine Technology:Two Knee Replacements May Be Better Than One 2NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 2NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 3NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 4NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 5
(Date:9/22/2014)... September 22, 2014 The Spa Standard, ... to lead the start-up in developing content and courses ... to the company over 15 years of experience in ... resort spa management with companies including Orient Express Hotels ... the role of educator, Jenny gained extensive industry insight ...
(Date:9/22/2014)... the proverbial needle in the cancer antigen haystack, according ... of Experimental Medicine . , As cancer ... creates new versions of proteins, some of which are ... cells, prompting the cells to attack and eliminate the ... of the mutations in a patient,s cancer and to ...
(Date:9/22/2014)... 2014--Women who are about to be released from prison ... if they are to successfully reintegrate into their communities ... study. , Almost half of all female prisoners are ... and most have multiple prison terms, mainly for drug-related ... Michael,s Hospital, conducted one-on-one interviews with women who were ...
(Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
(Date:9/22/2014)... on Trauma, patients with severe injuries should be treated ... centers have the resources to provide the best care ... major trauma patients in 2010 actually received their treatment ... a new study from the Center for Pediatric Trauma ... at Nationwide Children,s Hospital. Those patients are "undertriaged." The ...
Breaking Medicine News(10 mins):Health News:The Spa Standard Appoints Vice-President of Content and Course Development 2Health News:Involving female offenders in release planning can increase reintegration success 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 2Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 3
... Health plans today proposed guaranteed coverage for people with pre-existing ... , , Under the ... market would be required to offer coverage to all applicants ... individuals were required to maintain health insurance. , ...
... Inc. (NYSE: PRX ) today announced that it ... the U.S. to market budesonide,inhalation suspension, which is a generic ... asthma. Par began,shipping 0.25 mg/2 ml and 0.5 mg/2 ... Full-year US sales for PULMICORT(R) in 2007 totalled ...
... human trial , , WEDNESDAY, Nov. 19 (HealthDay News) -- ... patients may not slow the disease, new research suggests. ... spurred by promising animal research that had suggested that ... on the brain. , However, "the study suggests that ...
... , TORONTO, Nov. 19 /PRNewswire-FirstCall/ - Bradmer ... and commercialization of cancer therapies, announced today that it ... data from Neuradiab(TM) at the Society for Neuro-Oncology,s (SNO) ... from two previously conducted Phase II trials, is titled ...
... medicine community: "Are Your Cells Free?" Learn more about InVitria at TERMIS ... ... Collins, CO (PRWEB) November 19, 2008 -- Stem cell culture researchers ... Tissue Engineering Meeting TERMIS in San Diego on Dec. 7-10. ...
... anniversary of the adoption of the United Nations Convention on the ... ARLINGTON, Va., Nov. 19 The Child Welfare League of America ... Rights of the Child (CRC), the American Psychological Association, and the ... Children,s Health Issues and The Convention on the Rights of the ...
Cached Medicine News:Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 2Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 3Health News:Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately 2Health News:Growth Hormone Boost May Not Slow Alzheimer's 2Health News:Growth Hormone Boost May Not Slow Alzheimer's 3Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 2Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 3Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 4Health News:InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego 2Health News:Linda Spears, CWLA Vice President of Policy Will Speak at Senate Briefing 2
... November 2005. Specifications, including colors, subject to ... lb (2.3 kg), FreeStyle by AirSep is ... for those patients who know no boundaries. ... FreeStyle captures the heart of what it ...
... is AirSep Corporations most economical line of ... lpm of therapeutic oxygen in home, hospital, ... of units in daily use throughout the ... known for high performance, easy maintenance, and ...
... to 10 LPM of oxygen reducing the delivery ... M10 is engineered to reduce the cost of ... fewer parts than any other concentrator on the ... you to reduce expenditure on accessories and unnecessary ...
... conserver, it's important to have a choice that ... name synonymous with innovative excellence, offers two great ... automatic and value packed conservers., ,With its ... used 8 hours a day for 3 to ...
Medicine Products: